Q32 Bio Inc. announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata. The data demonstrated a mean percent reduction in SALT score from baseline of 35.3% in the prespecified modified intent-to-treat (mITT) analysis. The company intends to advance the drug into a registration-directed program in the first half of 2027.

Key Efficacy Results

The trial met its primary endpoint and showed clinically meaningful efficacy across various measures. The results indicated that 40.0% of patients in the mITT analysis and 30.3% of patients in the intent-to-treat (ITT) analysis achieved a SALT-20 response at Week 36. SALT-20 is defined as 80% of scalp hair coverage.

Safety and Tolerability

Bempikibart exhibited a generally well-tolerated safety profile consistent with prior studies, with no new safety signals observed. There were no serious adverse events or Grade 3 or higher adverse events related to treatment. The most common treatment-emergent adverse event was injection site reaction (ISR), occurring in 36.3% of patients, though these were primarily singular events with an incidence of 4% across all dose administrations. All ISRs were mild and resolved without intervention.

Trial Design and Next Steps

Part B of the SIGNAL-AA program was an open-label trial evaluating 33 patients with severe or very severe alopecia areata. The dosing regimen included an initial loading phase of 200mg weekly for four doses, followed by 200mg every other week for 32 weeks. The company plans to share full results from Part B at a future medical meeting. Q32 Bio will host a conference call and webcast today, July 13, 2026, at 8:00 a.m. ET to discuss the findings.

Q32 Bio has filed a prospectus with the U.S. Securities and Exchange Commission (SEC) regarding a proposed offering amounting to $300M. The filing provides the regulatory framework for the company to issue securities, outlining the intended use of proceeds and the structure of the deal.

The prospectus submission is a necessary step for the company to access capital markets. It includes financial statements, risk factors, and details about the business operations that potential investors will review before participating in the offering.

The $300M figure represents the target size of the offering, though the final amount raised may vary based on market conditions and investor demand. The securities being offered are subject to approval by the SEC before they can be sold to the public.